
    
      A Randomized, Double-Blind, Parallel-Group, 52-Week, Chronic-Dosing, Multi-Center Study to
      Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects with Moderate to
      Very Severe Chronic Obstructive Pulmonary Disease
    
  